Research

Hormonal

Intensive glycemic control (targeting HbA1c <6.0-6.5%) slows the progression of microvascular complications (retinopathy, nephropathy, neuropathy) in type 2 diabetes, but does not significantly reduce macrovascular events within the first 3-5 years of treatment.

For Type 2 Diabetes, keeping blood sugar very low (HbA1c <6.5%) protects your eyes, kidneys, and nerves, but this protection takes years to show up in heart health. Be aware that aggressive sugar lowering can increase the risk of dangerous low blood sugar episodes, so the target must be balanced carefully with your doctor.

StrongQualifiesHIGH confidence
Landmark clinical trials have demonstrated that intensive glycemic control slows progression of microvascular complications (retinopathy, nephropathy, and neuropathy)... Long-term follow-up has demonstrated that intensive glycemic control also decreases risk of macrovascular disease, albeit rigorous evidence of macrovascular benefit did not emerge for over a decade.
Simeon I. Taylor et al. · Journal of Clinical Investigation · 2021

Why this rating

Based on landmark randomized controlled trials (DCCT, UKPDS, ACCORD, ADVANCE).

Source

Pharmacological treatment of hyperglycemia in type 2 diabetes

Simeon I. Taylor et al. · Journal of Clinical Investigation · 2021

DOI 10.1172/jci142243

narrative_reviewCited 243×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →